MacroGenics Inc logo

MGNX - MacroGenics Inc News Story

$13.25 -0.1  -1.0%

Last Trade - 19/01/22

Sector
Healthcare
Size
Mid Cap
Market Cap £602.9m
Enterprise Value £383.1m
Revenue £85.3m
Position in Universe 3085th / 7398

BRIEF-Macrogenics Announces Publication Of Flotetuzumab Interim Phase 1/2 Clinical Trial Results In Blood

Tue 22nd September, 2020 9:30pm
Sept 22 (Reuters) - MacroGenics Inc  MGNX.O :
    * MACROGENICS ANNOUNCES PUBLICATION OF FLOTETUZUMAB INTERIM
PHASE
1/2 CLINICAL TRIAL RESULTS IN BLOOD

Source text for Eikon:  ID:nGNX1cfCV5 
Further company coverage:  MGNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.